Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Govt’s Reform Panel to Draw Up Framework by Next Summer for Permanent Telemedicine Rollout, with Reimbursement Policies
December 24, 2020
- MHLW’s FY2021 Budget Record 33 Trillion-Plus Yen
December 23, 2020
- MHLW Orders Label Revision for Xylocaine; Advising Careful Administration in Ears and Digits
December 23, 2020
- MHLW’s Health Policy Bureau Allocated 129 Million Yen for Setting Up R&D Promotion Network
December 23, 2020
- 700 Million Yen Allocated for COVID-19 Control Measures in FY2021: MHLW’s Pharm Safety Bureau
December 23, 2020
- 0.8% Add-On to Adjustment Rate Set to Soften Impact on Drug Distribution: MHLW
December 22, 2020
- MHLW Official Says Biz Suspension on Kobayashi Kako Inevitable
December 22, 2020
- MHLW to Draw Up Guideline for Collecting Plasma from People Recovering from Emerging Infectious Diseases
December 22, 2020
- MHLW Urges Drug Makers to Provide Timely, Appropriate Information When Product Shortages Occur
December 22, 2020
- Advisory Panel Shelves Decision on Avigan, Says No Clear Efficacy Shown for COVID-19
December 22, 2020
- Japan Govt to Compile Formulary Guidelines by FY2022: Reform Timeline
December 21, 2020
- Japan Saves 431.5 Billion Yen in Drug Price Cuts, Curbs Social Security Costs: FY2021 Draft Budget
December 21, 2020
- Next New Drug Listing Scheduled for Next April: MHLW
December 21, 2020
- Chuikyo OKs Outline of FY2021 Off-Year Re-Pricing; Only Market Price-Linked Rules to Be Applied
December 21, 2020
- PMDA Reviewing Safety Risks for Pomalyst, MabCampath
December 21, 2020
- Ministers Agree on 5%-Plus Price Discrepancy Line for Off-Year Re-Pricing; 59% Coverage for Innovative Meds, 88% for LLPs, 83% for Gx
December 18, 2020
- Avigan’s COVID-19 Use Up for PAFSC Review on December 21
December 17, 2020
- MHLW Earmarks 3 Billion Yen in FY2020 Extra Budget to Support Construction of API Facilities
December 17, 2020
- Govt Settles on Discrepancy Rate Threshold of “Above 5%” for Off-Year Drug Re-Pricing, 430 Billion Yen Reduction, 60% Coverage for Innovative Meds
December 17, 2020
- Japan Govt Eyes 4-6% Price Discrepancy Threshold for Off-Year Drug Re-Pricing
December 16, 2020
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…